China Biotech Weekly #5: FDA Accepts Ivonescimab BLA — PDUFA Date Set for November 14, 2026

This Week's Top Takeaway

The FDA has accepted the BLA for ivonescimab and assigned a PDUFA target action date of November 14, 2026. This makes ivonescimab the first China-originated bispecific antibody with a defined FDA approval timeline. If approved, it validates the entire CDE-to-FDA pathway for Chinese-developed biologics — and it happens just weeks before the OMB BCC list deadline. The timing is not lost on the industry.

BIOSECURE Watch

Status: 🟡 New Development

SEC risk factor disclosure wave continues. Approximately 8 public companies have now added BIOSECURE-related language to their annual filings. The disclosure language is converging around a standard template — suggesting outside counsel coordination on recommended risk factor text.

Notable pattern: every company disclosing BIOSECURE risk so far has WuXi manufacturing or testing contracts. No company has yet disclosed BGI-related BIOSECURE risk in SEC filings, despite BGI being the entity with the most certain BCC designation path.

Takeaways for BD Teams

November 14, 2026 is now the most important date on the China biotech calendar. The PDUFA date for the first China-originated bispecific to seek FDA approval. Mark it.

The HARMONi-3 and HARMONi-7 results will be even more important than the BLA. Head-to-head trials against pembrolizumab in first-line NSCLC could position ivonescimab as a pembrolizumab replacement — a $25B+ market opportunity. Watch for data readouts in 2026.

SEC BIOSECURE disclosures are a leading indicator. 8 companies and counting. If your company has WuXi or BGI exposure and hasn't added BIOSECURE risk factor language to your 10-K, your outside counsel is behind.

China Biotech Weekly is published every Thursday. For questions, tips, or deal intelligence, reach out at antony@chinabiointel.com. — Antony Tan